We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Esco Lifesciences announced today the close of an over-subscribed US$200 million Series A and Crossover round. The financing was led by Vivo Capital and Novo Holdings A/S, with participation from new investors including China Investment Corporation ...
The purpose of the project is to culture Vero cells, using a packed bed bioreactor to a high cell density, and produce live attenuated yellow fever virus (YFV).